Who
Jeffrey A. Rona
Cbfo
Company insider
Files Form 4 as: Cbfo, Ovid Therapeutics; Director, S&W Seed Co; Chief Financial Officer, Great Basin Scientific.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $27K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 8 Oct 2014
- Last trade
- 26 Feb 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,125 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —408,750 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —408,750 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,125 at $0.00 | filing |
| 23 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K8,541 at $1.45 | filing |
| 23 Feb 2026filed 2 Mar 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K8,541 at $1.45 | filing |
| 26 Feb 2025filed 28 Feb 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,1853,902 at $0.56 | filing |
| 20 Feb 2025filed 24 Feb 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —262,500 at $0.00 | filing |
| 20 Feb 2025filed 24 Feb 2025 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —43,750 at $0.00 | filing |
| 17 Dec 2024filed 19 Dec 2024 | S&W Seed Co | SEC FORM 4 Code A | —12,725 at $0.00 | filing |
| 30 Jul 2024filed 1 Aug 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —315,000 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —168,750 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —28,125 at $0.00 | filing |
| 15 Dec 2023filed 19 Dec 2023 | S&W Seed Co | SEC FORM 4 Code A | —151,525 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —194,399 at $0.00 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Feb 2022filed 4 Feb 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —218,750 at $0.00 | filing |
| 2 Jun 2021filed 10 Jun 2021 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 17 Dec 2020filed 21 Dec 2020 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Jeffrey A. Rona; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.